Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially blocks α1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy (MET) for distal ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* **Dosing Timing:** Administer 30 minutes after the same meal each day to ensure consistent bioavailability.
* **Maximum Dose:** 0.8 mg daily (if inadequate response at 0.4 mg after 2–4 weeks).
## Pediatric Dosing
* **Safety/Efficacy:** Not established in the pediatric population. Use is strictly off-label and typically managed by pediatric urology; dosing is patient-specific and not standardized.
## Dose Adjustments
* **Renal Impairment:** No initial dosage adjustment required.
* **Hepatic Impairment:** Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). Use caution in moderate impairment.
* **CYP3A4/2D6 Inhibitors:** Limit dose to 0.4 mg if co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole) or in known CYP2D6 poor metabolizers.
## Contraindications
* Known hypersensitivity to tamsulosin.
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, and fatigue.
* **Serious:** Orthostatic hypotension (syncope), priapism, and Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **Antihypertensives/PDE-5 Inhibitors:** May cause additive hypotensive effects; monitor blood pressure closely.
* **Strong CYP3A4 Inhibitors:** (e.g., clarithromycin, ritonavir, ketoconazole) significantly increase plasma concentrations of tamsulosin.
## Monitoring
* Monitor blood pressure periodically, especially following dose initiation or increase.
* Assess symptom improvement via International Prostate Symptom Score (IPSS).
* Screen for cataract surgery history, as the risk of IFIS is significant if the patient undergoes phacoemulsification.
## Clinical Pearls
* **Orthostasis:** The risk of postural hypotension is highest during the first few days of therapy or after dose escalation. Advise patients to rise slowly from a sitting or lying position.
* **Cataract Surgery:** Advise patients to inform their ophthalmologist that they are taking or have taken tamsulosin before scheduling cataract surgery.
* **Administration:** Capsules must be swallowed whole; do not crush, chew, or open, as this alters the controlled-release mechanism.
* **Efficacy:** While BPH symptom relief is usually observed within 1 week, full effect may take up to 2–4 weeks.
***
*Disclaimer: This information is for educational purposes only. Clinical protocols and prescribing guidelines may vary by institution and region. Always verify current prescribing information, contraindications, and drug-drug interactions using institutional formulary resources or authoritative databases like Lexicomp or Micromedex before clinical application.*
